SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other EventsItem 8.01. Other Events
On July 26, 2017, Second Sight Medical Products, Inc. (the Company) issued a press release announcing market entry into Russia, implanting the first patient with the Company's Argus® II Retinal Prosthesis System in Moscow. A copy of our press release entitled “Second Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System,” is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release issued July 26, 2017 |
SECOND SIGHT MEDICAL PRODUCTS INC ExhibitEX-99.1 2 s106955_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Second Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System – Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa – SYLMAR,…To view the full exhibit click here
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.